Multiple Myeloma Management

Multiple Myeloma Management icon

ASO Keyword Dashboard

Tracking 17 keywords for Multiple Myeloma Management in Apple App Store

Developer: Med Learning Group Category: medical

Multiple Myeloma Management tracks 17 keywords (1 keyword ranks; 16 need traction). Key metrics: 0% top-10 coverage, opportunity 69.4, difficulty 35.3, best rank 68.

Tracked keywords

17

1  ranked •  16  not ranking yet

Top 10 coverage

0%

Best rank 68 • Latest leader —

Avg opportunity

69.4

Top keyword: clinical

Avg difficulty

35.3

Lower scores indicate easier wins

Opportunity leaders

  • clinical

    Opportunity: 72.0 • Difficulty: 37.8 • Rank —

    Competitors: 24

    62.5
  • approved

    Opportunity: 72.0 • Difficulty: 37.5 • Rank —

    Competitors: 62

    60.8
  • novel

    Opportunity: 71.0 • Difficulty: 33.1 • Rank —

    Competitors: 26

    54.6
  • agents

    Opportunity: 71.0 • Difficulty: 34.6 • Rank —

    Competitors: 31

    57.1
  • trials

    Opportunity: 70.0 • Difficulty: 30.0 • Rank —

    Competitors: 21

    49.5

Unranked opportunities

  • clinical

    Opportunity: 72.0 • Difficulty: 37.8 • Competitors: 24

  • approved

    Opportunity: 72.0 • Difficulty: 37.5 • Competitors: 62

  • novel

    Opportunity: 71.0 • Difficulty: 33.1 • Competitors: 26

  • agents

    Opportunity: 71.0 • Difficulty: 34.6 • Competitors: 31

  • trials

    Opportunity: 70.0 • Difficulty: 30.0 • Competitors: 21

High competition keywords

  • data

    Total apps: 86,710 • Major competitors: 950

    Latest rank: — • Difficulty: 50.3

  • multiple

    Total apps: 68,593 • Major competitors: 1,058

    Latest rank: 88 • Difficulty: 49.3

  • important

    Total apps: 44,384 • Major competitors: 471

    Latest rank: — • Difficulty: 47.4

  • well

    Total apps: 43,962 • Major competitors: 485

    Latest rank: — • Difficulty: 47.0

  • management

    Total apps: 42,389 • Major competitors: 304

    Latest rank: — • Difficulty: 46.8

All tracked keywords

Includes opportunity, difficulty, rankings and competitor benchmarks

Major Competitors
multiple681004981

68,593 competing apps

Median installs: 200

Avg rating: 4.2

8868

1,058

major competitor apps

management691004777

42,389 competing apps

Median installs: 75

Avg rating: 4.1

304

major competitor apps

important691004778

44,384 competing apps

Median installs: 150

Avg rating: 4.2

471

major competitor apps

trials701003049

902 competing apps

Median installs: 400

Avg rating: 4.3

21

major competitor apps

data671005083

86,710 competing apps

Median installs: 150

Avg rating: 4.2

950

major competitor apps

well691004778

43,962 competing apps

Median installs: 150

Avg rating: 4.1

485

major competitor apps

considering701003050

995 competing apps

Median installs: 125

Avg rating: 4.1

10

major competitor apps

clinical721003863

5,442 competing apps

Median installs: 100

Avg rating: 4.2

24

major competitor apps

preliminary681002441

263 competing apps

Median installs: 50

Avg rating: 4.1

2

major competitor apps

mechanism701003050

964 competing apps

Median installs: 100

Avg rating: 4.0

7

major competitor apps

approved721003861

4,294 competing apps

Median installs: 150

Avg rating: 4.1

62

major competitor apps

novel711003355

1,831 competing apps

Median installs: 350

Avg rating: 4.2

26

major competitor apps

agents711003557

2,596 competing apps

Median installs: 100

Avg rating: 4.2

31

major competitor apps

recognizing701003049

906 competing apps

Median installs: 100

Avg rating: 4.1

7

major competitor apps

implementing691002847

654 competing apps

Median installs: 100

Avg rating: 4.2

0

major competitor apps

clinical trials671002236

136 competing apps

Median installs: 200

Avg rating: 4.4

1

major competitor apps

efficacy671002237

162 competing apps

Median installs: 100

Avg rating: 4.3

0

major competitor apps

17 keywords
1 of 1

App Description

Bispecific antibodies are a novel mechanism in the management in the relapsed/refractory multiple myeloma. Recognizing the mechanism of these agents as well as preliminary efficacy data is important in considering clinical trials and implementing approved bispecific antibodies in the management of multiple myeloma.